Olanzapine in the Treatment of Anorexia Nervosa

Phase 4

Completed

• Conditions: Anorexia Nervosa
• Interventions: Drug: placebo; Drug: olanzapine

• Registration Number: NCT00592930
• Lead Sponsor: Northwell Health

Brief Summary

This study compared 10 weeks of treatment with olanzapine versus placebo in adolescent females with anorexia nervosa-restricting type who were undergoing acute treatment on an inpatient unit or a day hospital program that specializes in the treatment of eating disorders.

Detailed Description

Not available

Study Timeline

• Study Start: 2000-06
• Primary Completion: 2004-12
• Study Completion: 2004-12
• Status Verified: 2008-01
• Study First Submitted: 2008-01-02
• Study First Submitted QC: 2008-01-11
• Last Update Submitted: 2008-01-11
• Study First Posted: 2008-01-14
• Last Update Posted: 2008-01-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 20

Inclusion Criteria

• Females, ages 12-23

Exclusion Criteria

• Binge-purge type

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
2	placebo	matching placebo
1	olanzapine	olanzapine

Primary Outcome Measures

Name	Time	Method
weight gain	10 weeks

Secondary Outcome Measures

Name	Time	Method
measures of psychiatric symptoms	10 weeks

Trial Locations

Locations (1)

Schneider Children's Hospital; 🇺🇸 New Hyde Park, New York, United States